Oct 2026· Medicine· Vol 105· 0 citations· 10 references
Medicine
TL;DR
Iptacopan served as a bridge to control hemolysis, while the subsequent addition of IST addressed the underlying autoimmune bone marrow failure and no breakthrough hemolysis, extravascular hemolysis, or drug-related adverse events were observed.
Abstract
Rationale: Aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome is a rare acquired hematopoietic stem cell disorder. Patients who respond poorly to conventional immunosuppressive therapy (IST) and corticosteroids face limited therapeutic options and a poor prognosis. This article reports on the use of iptacopan combined with IST for AA-PNH syndrome. Patient concerns: A previously healthy 24-year-old Han Chinese male presented with dizziness and fatigue and was found to have pancytopenia. He was initially treated with cyclosporine. However, 2 years after discontinuation, he developed acute hemolysis. After treatment with iptacopan, the patient’s hemolysis was quickly controlled, but he still required blood transfusions. Diagnoses: The patient was initially diagnosed with aplastic anemia through bone marrow examination, along with a paroxysmal nocturnal hemoglobinuria clone. After recurrent acute hemolysis, reexamination of the bone marrow and flow cytometry revealed partial deficiency of cluster of differentiation (CD) 55/CD59, and fluorescently labeled aerolysin-negative cells accounted for more than 90% of granulocytes and monocytes. Eventually, the diagnosis of AA-PNH syndrome was made. Interventions: After acute hemolysis was initially managed with steroids and IST, the patient was started on iptacopan to achieve rapid hemolysis control. Given persistent transfusion dependence due to bone marrow hypoplasia, immunosuppressants and hematopoietic stimulants (danazol and eltrombopag) were added while continuing iptacopan. The hematopoietic stimulants were discontinued after 3 months due to abnormal liver function tests, and the patient was maintained on iptacopan combined with IST. Outcomes: Iptacopan rapidly and effectively controlled hemolysis, and no breakthrough hemolysis, extravascular hemolysis, or drug-related adverse events were observed. Critically, iptacopan served as a bridge to control hemolysis, while the subsequent addition of IST (tacrolimus/cyclosporine) addressed the underlying autoimmune bone marrow failure. After combined treatment with iptacopan and IST, the patient’s blood cell count gradually recovered, hemoglobin returned to normal levels, and blood transfusion was no longer required. Lessons: This case suggests that iptacopan combined with IST may represent a potentially effective and safe therapeutic option for AA-PNH syndrome that is refractory to conventional IST and corticosteroids. Especially for AA-PNH patients with impaired bone marrow function and continuous dependence on blood transfusion, iptacopan combined with IST may be an effective and well-tolerated treatment regimen.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal bone marrow disorder caused by a mutation in the PIG-A gene and a deficiency of GPI-anchor proteins on the surface of blood cells. The clinical picture is characterized by chronic intravascular hemolysis, cytopenias, and thrombotic complications. Dia...
N. Chichkova, M. D. Madoyan, A. Aga et al.· Meditsinskiy sovet = Medical...· 0 citations
Assessment of the complexity of BTH in PNH patients receiving complement inhibitors, particularly in the setting of TPE and transfusion is provided, particularly in the setting of TPE and transfusion.
Ganesh Raman, Meghana Vivek, R. Hasan et al.· Transfusion· 0 citations
This review aims to summarize and synthesize current knowledge on the etiology, pathophysiology, diagnostic approach, and treatment strategies for pancytopenia in SLE, as well as its differentiation from other causes of bone marrow failure.
Oliwia Kubiś, Katarzyna Wojakowicz, Zuzanna Rzepkowska et al.· Advances in Clinical and Exp...· 0 citations
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by complement-mediated hemolysis. Although C5 inhibitors effectively control intravascular hemolysis, some patients develop clinically significant extravascular hemolysis (EVH) because of upstream C3 deposition. A 56-year-old woman was diagnosed with PNH in 201...
Yewon Park, Hyunju Lee· Blood Research· 0 citations
Hepatitis-associated aplastic anemia (HAAA) is a rare but life-threatening subtype of acquired aplastic anemia (AA) that predominantly affects children and adolescents, characterized by bone marrow failure developing weeks to months following acute hepatitis. Although HAAA accounts for a small proportion of AA cases, i...
Emily Liao, Shova Subedi, V. Kasper et al.· European Journal of Haematol...· 0 citations
Case Presentation: A 37-year-old woman with acetylcholine receptor antibody–positive myasthenia gravis received high-dose intravenous immunoglobulin (2 g/kg over 5 days) due to progressive generalized weakness, mild left ptosis and myasthenic facies. She had no features of respiratory distress and was discharged after...
Jeffet Lucas Silva Fernandes, Luís Henrique Jufo, Luiz Fernando Matias et al.· ANPAbstract_CBN26· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.